#None #DelveInsight #cancer cachexia #Ponsegromab

Overview of Cancer Cachexia Market Growth

The cancer cachexia market is poised for impressive growth over the forecast period extending from 2025 to 2034, with a projected compound annual growth rate (CAGR) of 8.9%. This growth trajectory is expected across seven major markets (7MM), driven by the introduction of innovative treatments such as ponsegromab (PF-06946860), S-pindolol benzoate (ACM-001.1), and TCMCB07 among others. The rise in the prevalence of cancer cachexia relates closely to multiple factors, particularly the aging population and an increase in the survival rate of cancer patients, which makes cachexia more prevalent.

Understanding Cancer Cachexia

Cancer cachexia is a multifactorial disorder that leads to severe weight loss and muscle depletion in patients with advanced cancer. Unlike standard malnutrition, cancer cachexia is resistant to nutritional support. It is primarily driven by systemic inflammation, which affects metabolic processes and leads to a significant decrease in appetite and energy levels. As cancer types such as lung and pancreatic cancers become more prevalent, so does the incidence of cachexia, presenting significant challenges in clinical management.

Market Insights and Current Landscape

DelveInsight’s report on the cancer cachexia market highlights crucial insights regarding treatment options and market dynamics:

• - As of 2024, the market size for cancer cachexia in the 7MM was valued at approximately USD 475 million.
• - Notably, the United States occupies a significant portion of the market, accounting for around 58% of the total market share. This positions it as the largest contributor to cancer cachexia-related treatments compared to the EU4 countries and Japan.

Despite currently available treatments including progestins and corticosteroids providing modest benefits, there remains a considerable unmet need for more effective therapies. In 2024, standard care therapies grossed around USD 470 million, further emphasizing this gap.

The study also projected that approximately 1.4 million diagnosed cases of cancer cachexia were anticipated in the 7MM in 2024, with numbers expected to rise leading into 2034.

Promising Treatments on the Horizon

Several leading pharmaceutical companies such as Pfizer and Actimed Therapeutics are developing novel therapies targeting cancer cachexia. Key pipeline therapies currently in development include:

• - Ponsegromab (PF-06946860) by Pfizer, projected to generate about USD 425 million in revenues from the 7MM by 2034.
• - S-pindolol benzoate (ACM-001.1; MT-102) from Actimed Therapeutics.
• - TCMCB07 and Rilogrotug (AV-380), both showing promise in clinical trials.

Challenges in Treatment

The treatment of cancer cachexia poses significant challenges. Many patients with cachexia respond poorly to chemotherapy and have an increased risk of infections and mortality, with studies indicating that up to 30% of these patients may die from cachexia as opposed to their cancer. Furthermore, the economic burden on patients from cachexia treatment can significantly impact their quality of life. Healthcare issues such as a lack of specialists and the challenges surrounding the diagnosis of cachexia complicate the situation further.

To combat these challenges, new strategies focusing on cytokine-targeted therapies aim to mitigate weight loss and muscle degradation. These therapies stimulate an intricate response in various bodily systems related to muscle and fat loss, offering potential hope for future interventions.

Conclusion

As the cancer cachexia market continues to evolve, the introduction of novel therapies and increasing awareness of the condition will likely identify new treatment pathways. The anticipated rise in diagnosed cases paired with market expansion signals vital opportunities for pharmaceutical innovation and growth. Ongoing development and clinical trials will play a crucial role in shaping the future landscape of cancer cachexia treatment, ultimately enhancing patient care and outcomes across multiple demographics.